Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Processing of MIA protein during melanoma cell migration
International Journal of Cancer, 06/16/09
Schmidt J et al. - In a study to gain a detailed understanding of the processes of melanoma inhibitory activity (MIA) protein function, it was found that as MIA protein has a major contribution to the aggressive characteristics of malignant melanoma in particular to formation of metastasis, it is important to elucidate the MIA functional mechanism in tumor cells to find novel therapeutic strategies in the fight against skin cancer.
Methods- In this study, it was shown that after binding of MIA protein to integrin α5β1, MIA protein is internalized together with this cell adhesion receptor at the cell rear.
- This mechanism enables tumor cells to migrate in a defined direction as appropriate for invasion processes.
- Treatment of melanoma cells with PKC-inhibitors strongly reduced internalization of MIA protein.
- Endocytosis is followed by dissociation of MIA-integrin complexes.
- In acidic vesicles MIA protein is degraded while integrins are recycled.
- Treatment of melanoma cells with MIA inhibitory peptides almost completely blocked the MIA protein uptake into cells.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Clinical Cancer Research, 11/06/09
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/03/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


